Evidence map›Paper›PMID 33083905›Full record

ArticleCancer immunology, immunotherapy : CII2021

Notch signaling defects in NK cells in patients with cancer.

Gulnur K Zakiryanova, Elena Kustova, Nataliya T Urazalieva, Emile T Baimukhametov, Valeriy A Makarov, Gulmariya M Turaly, Galina V Shurin, Zarema M Biyasheva, Narymzhan N Nakisbekov, Michael R Shurin

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Notch signaling pathway: architecture, disease, and therapeutics.Signal transduction and targeted therapy · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Gulnur K ZakiryanovaAl-Farabi Kazakh National University, Almaty, Kazakhstan. gzakiryanova@gmail.com.ORCID http://orcid.org/0000-0002-7267-6312
Elena KustovaLaboratory of Immunology, Scientific Center of Pediatric and Children Surgery, Almaty, Kazakhstan.
Nataliya T UrazalievaLaboratory of Immunology, Scientific Center of Pediatric and Children Surgery, Almaty, Kazakhstan.
Emile T BaimukhametovDepartment of Oncology, Kazakh Medical University of Continuing Education, Almaty, Kazakhstan.
Valeriy A MakarovDepartment of Oncosurgery, Almaty Oncology Center, Almaty, Kazakhstan.
Gulmariya M TuralyJoint Use Center, Atchabarov Scientific Research Institute of Fundamental and Applied Medicine, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Galina V ShurinDepartments of Pathology and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Zarema M BiyashevaAl-Farabi Kazakh National University, Almaty, Kazakhstan.
Narymzhan N NakisbekovJoint Use Center, Atchabarov Scientific Research Institute of Fundamental and Applied Medicine, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan.
Michael R ShurinDepartments of Pathology and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. shurinmr@upmc.edu.
Kazakhstan Medical University · KZAl-Farabi Kazakh National University · KZKazakh National Medical University · KZUniversity of Pittsburgh Medical Center · USKazakh Institute of Oncology and Radiology · KZ

Funding

Ministry of Education and Science of the Republic of Kazakhstan №AP05130612
6 · The paper itself

Abstract

Altered expressions of proto-oncogenes have been reported during normal lymphocytes mitogenesis and in T and B lymphocytes in patients with autoimmune diseases. We have recently demonstrated a significantly decreased expression of c-kit and c-Myc in NK cells isolated from patients with cancer, which might be related to the functional deficiency of NK cells in the tumor environment. Here, focusing on the regulatory mechanisms of this new clinical phenomenon, we determined expression of c-Myc, Notch1, Notch2, p-53, Cdk6, Rb and phosphorylated Rb in NK cells isolated from the healthy donors and cancer patients. The results of our study revealed a significant down-regulation of expression of Notch receptors and up-regulation of Cdk6 expression in NK cells in cancer, while no significant changes in the expression of p53 and Rb proteins were seen. These data revealed novel signaling pathways altered in NK cells in the tumor environment and support further investigation of the origin of deregulated expression of proto-oncogenes in NK cells patients with different types of cancer.

Indexed as

AdultAgedBiomarkers, TumorCase-Control StudiesCyclin-Dependent Kinase 6FemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKiller Cells, NaturalMaleMiddle AgedNeoplasmsPrognosisReceptor, Notch1Receptor, Notch2Biomarkers, TumorCDK6 protein, humanCyclin-Dependent Kinase 6NOTCH1 protein, humanNOTCH2 protein, humanReceptor, Notch1Receptor, Notch2c-mycNK cellsNotch1Notch2T cells

Identifiers

PMID33083905
PMCPMC10991167
OpenAlexW3094571849

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.